中东呼吸综合征的临床治疗和小分子治疗药物研究进展

发布时间：2018-05-25 19:52

本文选题：中东呼吸综合征 + 中东呼吸综合征冠状病毒　；参考：《国际药学研究杂志》2015年03期

【摘要】：中东呼吸综合征(MERS)是由新型冠状病毒MERS-CoV感染引起的传染病,2012年在沙特被首次发现,疫情主要集中在中东地区,在欧洲、非洲、北美洲和亚洲也有少量病例报告,近期韩国连续报告数十病例,并且1例经香港输入中国大陆地区。目前,临床上尚无针对MERS-CoV的特异性抗病毒药物和治疗方法,主要是对症治疗,在防止并发症的同时实施有效的呼吸、循环支持和肾功能保护。本文对文献报道的潜在临床治疗方法,抗MERS-CoV的潜在药物靶点和小分子治疗药物的研究进展进行综述。
[Abstract]:MERS, an infectious disease caused by a new type of coronavirus MERS-CoV infection, was first discovered in Saudi Arabia in 2012. The epidemic is concentrated in the Middle East, with a small number of cases reported in Europe, Africa, North America and Asia. Dozens of cases have been reported in South Korea recently, and one case has been imported into mainland China via Hong Kong. At present, there are no specific antiviral drugs and treatments for MERS-CoV, mainly for symptomatic treatment, which can prevent complications while implementing effective respiratory, circulatory support and renal function protection. In this review, the potential clinical treatment methods, potential drug targets of anti-MERS-CoV and the research progress of small molecular therapy drugs reported in the literature were reviewed.
【作者单位】：国家应急防控药物工程技术研究中心军事医学科学院毒物药物研究所;
【基金】：国家重大新药创制科技重大专项资助项目专项(2014ZX09304-001)
【分类号】：R511

【共引文献】